Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses…
News
Omnipod 5 improves glycaemic levels in people transitioning from daily injections
NACE to launch trial in Australia for young people with hay fever
Roche’s discontinued Alzheimer’s drug shows signs of preventing onset
Novartis reports Phase III efficacy and safety outcomes of SMA treatment
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old
Flatiron and NRG Oncology to deploy EHR-to-EDC technology in multi-centre trial
Immunovant will not seek approval for MG therapy, despite hitting endpoints
